Lettmann Jason 4

What Happened

• Jason Lettmann, CEO of ALX Oncology (ALXO), had 2,201 shares withheld on 2026-02-17 to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs). The withholding was executed at $2.27 per share, totaling $4,996. This was a tax-withholding disposition (transaction code F), not an open-market sale.

Key Details

• Transaction date and price: 2026-02-17 at $2.27 per share (2,201 shares withheld; $4,996 total).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — shares were withheld to satisfy the reporting person's tax liability on vested RSUs; F2 — the reporting person's holdings include 3,000 shares acquired under the issuer's employee stock purchase plan on 12/31/2025.
• Filing timing: Form filed 2026-02-19 for a 2026-02-17 transaction; appears to be timely (no late-filing flag noted).

Context

• This was a routine tax-withholding event tied to RSU vesting (cashless/withheld shares), not an intentional open-market sale or purchase. Such withholding is administrative and does not, by itself, indicate a change in insider sentiment.